Trial Profile
A Double-Blind, Randomised, Placebo Controlled Study of the Efficacy and Safety and Pharmacokinetics of Orvepitant in Subjects With Pruritus Associated With Atopic Dermatitis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 22 May 2018
Price :
$35
*
At a glance
- Drugs Orvepitant (Primary)
- Indications Atopic dermatitis; Pruritus
- Focus Therapeutic Use
- Acronyms SOOTHE
- Sponsors NeRRe Therapeutics
- 09 May 2018 Status changed from not yet recruiting to withdrawn prior to enrolment due to strategic decision
- 16 Mar 2018 New trial record